Xeris Biopharma Holdings, Inc. XERS Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $83.13M+38.3% | $85.81M+42.8% | $74.38M+37.1% | $71.54M+48.8% | $60.12M+47.9% | ||
| $10.57M+21.2% | $10.95M+15.5% | $11M-19.1% | $11.9M+52.7% | $8.73M+46.2% | ||
| $8.78M+13.3% | $7.87M+29.3% | $7.48M+27.1% | $8.06M+39.9% | $7.75M-0.9% | ||
| $53.14M+20.7% | $47.5M+18.3% | $46.46M+3.3% | $44.39M+11.0% | $44.02M+14.7% | ||
| $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | ||
| $75.21M+19.0% | $69.03M+18.2% | $67.65M+0.7% | $67.06M+19.2% | $63.21M+15.2% | ||
| $7.92M+356% | $16.77M— | $6.73M+152% | $4.48M+155% | -$3.09M+78.3% | ||
| 9.5%+14.7pp | 19.5%+19.5pp | 9%+32.8pp | 6.3%+23.3pp | -5.1%+29.9pp | ||
| $6.88M-5.8% | $7.15M-7.1% | $7.27M-6.7% | $7.36M-7.6% | $7.31M+3.9% | ||
| $1.2M+2.3% | $1.46M+60.5% | $1.16M-3.3% | $948K-26.6% | $1.18M-38.9% | ||
| -$5.68M+7.3% | -$5.69M+16.2% | -$6.11M+1.0% | -$6.41M-5.6% | -$6.13M-38.4% | ||
| $0— | $0— | $0+100% | $0-100% | $0-100% | ||
| $2.23M+124% | $11.08M+317% | $621K+104% | -$1.93M+87.2% | -$9.22M+51.4% | ||
| 2.7%+18.0pp | 12.9%+21.4pp | 0.8%+29.8pp | -2.7%+28.5pp | -15.3%+31.4pp | ||
| $0.01+117% | $0.07+333% | $0.00+100% | -$0.01+90.0% | -$0.06+57.1% | ||
| $0.01+117% | $0.07+333% | $0.00+100% | -$0.01+90.0% | -$0.06+57.1% | ||
| 177.6M+16.5% | 172.7M+17.7% | 177.6M+19.2% | 159.5M+7.5% | 152.4M+8.5% | ||
| 170.5M+11.9% | 160.4M+9.3% | 163.6M+9.8% | 159.5M+7.5% | 152.4M+8.5% | ||
| $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | ||
| $2.24M+124% | $11.08M+316% | $620K+104% | -$1.93M+87.2% | -$9.22M+51.5% | ||
| $1.2M+2.3% | $1.46M+60.5% | $1.16M-3.3% | $948K-26.6% | $1.18M-38.9% | ||
| $1K— | —— | -$1K— | $1K0.0% | $0+100% | ||
| -$5.68M+7.3% | -$5.69M+16.2% | -$6.11M+1.0% | -$6.41M-5.6% | -$6.13M-38.4% | ||
| $83.13M+38.3% | $85.81M+42.8% | $74.38M+37.1% | $71.54M+48.8% | $60.12M+47.9% | ||
| $7.92M+356% | $16.77M— | $6.73M+152% | $4.48M+155% | -$3.09M+78.3% | ||
| $8.25M+397% | $17.11M+5,366% | $7.07M+156% | $4.81M+161% | -$2.78M+80.1% | ||
| $8.25M+397% | $17.11M+5,366% | $7.07M+156% | $4.81M+161% | -$2.78M+80.1% | ||
| 9.9%+14.5pp | 19.9%+19.4pp | 9.5%+32.7pp | 6.7%+23.2pp | -4.6%+29.6pp | ||
| $7.92M+356% | $16.77M— | $6.73M+152% | $4.48M+155% | -$3.09M+78.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s revenue?
- Xeris Biopharma Holdings, Inc. (XERS) generated $314.9M in revenue over the trailing twelve months, up 41.5% year over year.
- Is Xeris Biopharma Holdings, Inc. profitable?
- Xeris Biopharma Holdings, Inc. reported $12.0M in net income over the trailing twelve months, a 3.8% net margin.
- What are Xeris Biopharma Holdings, Inc.'s profit margins?
- Gross margin is 85.9% and operating margin is 11.4%, with a 3.8% net margin.
- What is Xeris Biopharma Holdings, Inc.'s earnings per share?
- Xeris Biopharma Holdings, Inc.'s diluted EPS over the trailing twelve months is $0.07.
- Where does Xeris Biopharma Holdings, Inc.'s income statement data come from?
- Every line is extracted from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
